Ecopia BioSciences Inc.

Ecopia BioSciences Inc.

November 15, 2005 15:23 ET

Ecopia Presents Breast and Prostate Cancer Data at AACR-NCI-EORTC

MONTREAL, QUEBEC--(CCNMatthews - Nov. 15, 2005) - Ecopia BioSciences Inc. (TSX:EIA) is pleased to announce that it is presenting a scientific poster demonstrating that its lead compound, ECO-4601, is active in vivo against breast and prostate cancer. This poster is presented today in Philadelphia, Pennsylvania at the oncology conference sponsored by the American Association for Cancer Research (AACR), jointly with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC). The data has originally been disclosed by way of a press release dated May 17, 2005.

Additional data included in the poster is showing that ECO-4601 needs long-term exposure in order to highlight its potency. "This characteristic is very important in the design of our upcoming Phase I, where patients will be exposed to the compound's potential benefits over prolonged continuous administration", commented Pierre Falardeau, President and Chief Executive Officer of the Company. "The safety profile of ECO-4601 is such that long-term exposure is not a problem", he added.

A copy of the poster is available on Ecopia's website at under "News - Scientific Publications".

About Ecopia

Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to move our flagship compound ECO-4601 into Phase I clinical trials. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology. The common shares of Ecopia are listed on the TSX (symbol: EIA).

Additional information about the Company can be obtained from Ecopia's website at

This press release may contain forward-looking statements that reflect the Company's current expectations regarding future events. The forward-looking statements, including expectations as to the pharmaceutical potential of ECO-4601 in humans, the pharmaceutical potential of ECO-4601 in specific cancer indications and the effect of long-term exposure of ECO-4601 involve risk and uncertainties. Actual events could differ materially from those projected here and depend on a number of factors, including scientific uncertainties relating to the correlation between preclinical animal data and human clinical data, uncertainties related to the regulatory process for drug development and the success and timely completion of clinical studies and trials, and the impact of general economic conditions. Investors are cautioned against placing undue reliance on forward-looking statements. A more complete discussion of the risks and uncertainties facing the Company appears in Ecopia's 2004 Annual Report.

Contact Information